Bengaluru-based online pharmacy startup PlatinumRx is reportedly in discussions to raise approximately $32 Mn (more than Rs 300 Cr) in a funding round led by Belgium-based investment firm Sofina. The proposed transaction could value the company between $150 Mn and $200 Mn, or approximately Rs 1,400 Cr to Rs 1,878 Cr.
The discussions are ongoing, and the final investment amount, valuation and participation of other investors have not been confirmed. If completed, the transaction would represent a significant step-up in capital for the company as it expands its affordable-medicine delivery business in India.
According to the reported discussions, PlatinumRx is seeking fresh capital to strengthen its operations and build its position in the competitive online pharmacy market.
Sofina Emerges As Potential Lead Investor
Sofina, a Belgium-based investment holding company with an international investment portfolio, is reportedly leading the proposed funding discussions.
The participation of existing investors, including Stellaris Venture Partners and India Quotient, remains unclear. Queries to PlatinumRx and Sofina had not received responses at the time of the initial report.
The proposed $32 million investment comes roughly a year after PlatinumRx raised $6 million in its Series A round in September 2025. That round was led by Stellaris Venture Partners, with participation from existing investor India Quotient.
Before the Series A, the startup raised approximately $800,000 in a seed round in April 2024, also led by India Quotient.
The new round, if finalised, would mark a substantial increase in the company's funding base. However, the reported $150 million–$200 million valuation is still a discussion-stage estimate, not a confirmed post-money valuation.
Ashutosh Pandey And Piyush Kumar Founded PlatinumRx
Founded in 2023 by Ashutosh Pandey and Piyush Kumar, PlatinumRx operates an online pharmacy focused on making prescription medicines more affordable, particularly for people who require regular medication for chronic conditions.
The platform helps customers identify alternative brands with the same salt composition as prescribed medicines. Its model aims to reduce the cost of recurring prescriptions by offering alternatives to more expensive branded products.
The company says it sources medicines directly from pharmaceutical manufacturers and follows quality checks before making products available to customers.
This approach targets a persistent problem in India's healthcare market: the affordability of long-term medication. For patients managing conditions such as diabetes and hypertension, even small differences in monthly medicine costs can accumulate into a significant financial burden.
PlatinumRx says it has served more than 10 lakh customers through its platform, reflecting the demand it is targeting beyond traditional pharmacy channels.
Previous Funding Supported Supply Chain Expansion
The company's $6 million Series A round in September 2025 was intended to strengthen its fulfilment network, expand product and technology teams, improve sourcing efficiencies and build brand awareness.
At the time, PlatinumRx outlined plans to add five fulfilment centres over the following 12–18 months. It also planned to use technology and AI-driven personalisation to improve the customer experience.
The proposed new funding could provide additional resources for expanding fulfilment capacity, strengthening pharmaceutical sourcing and improving delivery operations. However, the company has not publicly confirmed a detailed utilisation plan for the potential $32 million round.
Revenue Growth And The Economics Of Online Pharmacy
PlatinumRx's operating model is built around repeat medicine purchases rather than only occasional healthcare orders. This gives it an opportunity to develop recurring customer relationships, particularly among people who need regular prescriptions.
The company's FY25 financials provide an early indication of its growth trajectory. Afforis Health Technologies Private Limited, the entity operating the PlatinumRx business, reported revenue of approximately Rs 10.67 crore in FY25, compared with around Rs 13.4 lakh in FY24. Its net loss stood at approximately Rs 7.28 crore during FY25.
These figures point to rapid growth from a small revenue base, but also show that the business was loss-making in the financial year for which these numbers are available. They should not be treated as the company's current revenue run rate.
For investors, the next stage will involve assessing whether higher order volumes can translate into stronger gross margins, repeat purchases and more efficient customer acquisition.
Competition In India's Online Pharmacy Market
PlatinumRx is entering a market where established online pharmacy businesses and newer quick-commerce companies are competing for medicine orders.
Companies such as Truemeds have built businesses around affordable medicine alternatives, while quick-commerce platforms are expanding their healthcare and pharmacy offerings to capture time-sensitive demand.
The distinction in PlatinumRx's model is its focus on substitute medicines and affordability, rather than competing only on delivery speed.
That positioning could help it attract customers with recurring medication requirements. However, the business must maintain reliable sourcing, medicine quality, regulatory compliance and fulfilment efficiency as it expands.
If the proposed Sofina-led round closes, PlatinumRx will have an opportunity to scale its model with a larger pool of institutional capital. The bigger test will be whether it can convert its customer growth into a sustainable and profitable online pharmacy business.
Editorial notes
-
Funding status: The proposed $32 Mn round is reported to be under discussion. Do not describe it as closed, raised or secured.
-
Valuation: The $150 Mn-$200 Mn range is indicative and unconfirmed. Do not present $200 Mn as the company's final valuation.
-
Investor participation: Sofina is reported to be leading the discussions. Participation by existing investors has not been confirmed.
-
Founders: Ashutosh Pandey and Piyush Kumar are both confirmed co-founders and have been included.
-
Financials: FY25 revenue of Rs 10.67 Cr and net loss of Rs 7.28 Cr relate to the operating entity's reported financials. They are not current FY26 figures.
-
Customer base: The company's website claims more than 10 lakh customers; this is a company reported figure, not an independently audited customer count.